SeqSore version 4.5
[illegible] 2002 [illegible]

[illegible] sw model

[illegible] 10:18:49 ; [illegible] 4 Seconds
(Wildcard alignments)
[illegible] Million cell updates/sec

[illegible]

[illegible]VALSYILA[illegible] [illegible]NMEKALKILKIEL 175

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible] summaries

[illegible]
[illegible]
[illegible]
[illegible]
[illegible]
[illegible]
[illegible]

[illegible] results predominantly appear to have a
equal to the score of the result being printed.
[illegible]ysis of the total score distribution.

SUMMARIES

| [illegible] | ID | Description |
|---|---|---|
| [illegible] | US-08-916-576B-2 | Sequence 2, Appli |
| [illegible] | US-09-247-155-106 | Sequence 106, App |
| [illegible] | US-08-916-576B-8 | Sequence 8, Appli |
| [illegible] | US-09-247-155-174 | Sequence 174, App |
| [illegible] | US-08-916-576B-6 | Sequence 6, Appli |
| [illegible] | US-08-916-576B-7 | Sequence 7, Appli |
| [illegible] | US-08-916-576B-4 | Sequence 4, Appli |
| [illegible] | US-08-884-687-5 | Sequence 5, Appli |
| [illegible] | US-09-258-64[illegible]-5 | Sequence 5, Appli |
| [illegible] | US-08-560-[illegible]-7 | Sequence 7, Appli |
| [illegible] | US-09-418-54[illegible]-7 | Sequence 7, Appli |
| [illegible] | US-09-534-[illegible]-5 | Sequence 5, Appli |
| [illegible] | PCT-US92-[illegible]-4 | Sequence 4, Appli |
| [illegible] | US-09-013-[illegible]-5 | Sequence 5, Appli |
| [illegible] | US-08-313-[illegible]-53 | Sequence 53, Appl |
| [illegible] | US-08-459-[illegible]-17 | Sequence 17, Appl |
| [illegible] | US-09-[illegible]-14A-54 | Sequence 54, Appl |
| [illegible] | US-08-[illegible]-52 | Sequence 52, Appl |
| [illegible] | US-09-[illegible]-8 | Sequence 8, Appli |
| [illegible] | US-09-[illegible]-8 | Sequence 8, Appli |
| [illegible] | US-09-652-[illegible]-22 | Sequence 22, Appl |
| [illegible] | US-08-834-[illegible]-22 | Sequence 22, Appl |
| [illegible] | US-09-503-[illegible]-22 | Sequence 22, Appl |
| [illegible] | US-08-[illegible]-2 | Sequence 2, Appli |
| [illegible] | US-08-[illegible]-2 | Sequence 2, Appli |
| [illegible] | US-[illegible]-2 | Sequence 2, Appli |
| [illegible] | US-[illegible]-11 | Sequence 11, Appl |
| 28 | 67.5 | 7.5 | 27[illegible] | 4 | US-08-[illegible]-89 | Sequence 89, Appl |
| 29 | 66.5 | 7.4 | 45[illegible] | 2 | US-08-[illegible]-3A-18 | Sequence 18, Appl |
| 30 | 66.5 | 7.4 | 46[illegible] | 2 | US-08-[illegible]-4A-17 | Sequence 17, Appl |
| 31 | 66.5 | 7.4 | 49[illegible] | 2 | US-08-[illegible]-5A-5 | Sequence 5, Appli |
| 32 | 66.5 | 7.4 | 4[illegible] | 2 | US-08-[illegible]-9A-16 | Sequence 16, Appl |
| 33 | 66.5 | 7.4 | 95[illegible] | 4 | US-09-295-186-10 | Sequence 10, Appl |
| 34 | 66.5 | 7.4 | 57[illegible] | 4 | US-09-295-186-11 | Sequence 11, Appl |
| 35 | 66.5 | 7.4 | 1[illegible]68 | 1 | US-08-[illegible]57-21-A-2 | Sequence 2, Appli |
| 36 | 66.5 | 7.4 | 100[illegible] | 4 | US-07-[illegible]-11-825-2 | Sequence 2, Appli |
| 37 | 66.5 | 7.4 | 2556 | 1 | US-08-[illegible]45-43[illegible]-17 | Sequence 17, Appl |
| 38 | 66 | 7.3 | 516 | 1 | US-08-[illegible]-11A-41 | Sequence 41, Appl |
| 39 | 66 | 7.3 | 616 | 2 | US-08-[illegible]-74[illegible]-2 | Sequence 2, Appli |
| 40 | 66 | 7.3 | 28[illegible] | 1 | US-08-[illegible]-[illegible]-15 | Sequence 15, Appl |
| 41 | 66 | 7.3 | 28[illegible] | 1 | US-08-[illegible]-11A-2 | Sequence 2, Appli |
| 42 | 66 | 7.3 | 28[illegible] | 2 | US-08-414-[illegible]-15 | Sequence 15, Appl |
| 43 | 66 | 7.3 | 28[illegible] | 2 | US-08-[illegible]-154-15 | Sequence 15, Appl |
| 44 | 66 | 7.3 | 28[illegible] | 2 | US-08-[illegible]-15 | Sequence 15, Appl |
| 45 | 66 | 7.3 | 28[illegible] | 2 | US-08-[illegible]-15 | Sequence 15, Appl |

ALIGNMENTS

RESULT 1
US-08-916-576B-2
; Sequence 2, Application [illegible]
; Patent No. 6171816
; GENERAL INFORMATION:
; APPLICANT: YU, GUO-LIANG
; APPLICANT: DILLON, PATRICK J.
; APPLICANT: BENEF, BERNARD
; APPLICANT: ENGLEBIENNE, THIERRY A.
; TITLE OF INVENTION: A VIRUS HUMAN IMMUNODEFICIENCY
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
; STREET: 1100 NEW YORK AVENUE, SUITE 600
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: US
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.3
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/916,576B
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/024,447
; FILING DATE: 23-AUG-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: STEFFE, ERIC K.
; REGISTRATION NUMBER: 36,688
; REFERENCE/DOCKET NUMBER: 1488.0540000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 175 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-916-576B-2

Query Match [illegible] %; Score [illegible]; DB 4; Length 175;
Best Local Similarity [illegible] %; Pred. No. [illegible] e-[illegible];
Matches 175; Conservative [illegible]; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];



SeqData version 1.7
(c) 1993 - 2000 Geospan Corp.

Local SW mode )

2:41:33 ; Search Time 2.08 Seconds
(Xeon 2.0Z elements)
1.0+-2+ Million cell updates/sec

% Alignment

Matrix: BLOSUM62 Gap Penalty: 10 Extension: 1.0

Length adjustment: 2

Result set 1: 1275 positions

Query Match Threshold parameter: 0.766

Searching

Total number of hits satisfying chosen parameters:

Minimum DB seq length:

Maximum DB seq length:

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : pctdata/2/ina/5A_COMB.seq:*
pctdata/2/ina/5B_COMB.seq:*
pctdata/2/ina/6A_COMB.seq:*
pctdata/2/ina/6B_COMB.seq:*
pctdata/2/ina/PCTFULL.seq:*
pctdata/2/ina/Rejects_COMB.seq:*

Total number of results predicted by chance to have a
score equal to the score of the result being printed.
Results of the total score distribution.

SUMMARIES

| | Result No. | Score | Query Match | Length | DB | ID | Description |
|---|---|---|---|---|---|---|---|
| | 1 | 875 | 100.0 | 875 | 4 | US-08-916-576B-1 | Sequence 1, Appli |
| | 2 | 247 | 28.2 | 247 | 4 | US-09-247-150-1 | Sequence 61, Appl |
| | 3 | 247 | 28.2 | 247 | 4 | US-09-247-150-11 | Sequence 149, App |
| | 4 | 240 | 27.4 | 240 | 4 | US-09-040-984-78 | Sequence 78, Appl |
| | 5 | 240 | 27.4 | 240 | 4 | US-09-123-913-78 | Sequence 78, Appl |
| | 6 | 221 | 25.3 | 221 | 4 | US-09-221-276-32 | Sequence 32, Appl |
| | 7 | 218 | 24.9 | 218 | 4 | US-08-916-576B-35 | Sequence 35, Appl |
| | 8 | 218 | 24.9 | 218 | 4 | US-08-916-576B-9 | Sequence 9, Appli |
| | 9 | 218 | 24.9 | 218 | 4 | US-08-916-576B-36 | Sequence 36, Appl |
| | 10 | 218 | 24.9 | 218 | 4 | US-08-916-576B-10 | Sequence 10, Appl |
| | 11 | 218 | 24.9 | 218 | 4 | US-08-916-576B-5 | Sequence 5, Appli |
| | 12 | 209 | 23.9 | 209 | 4 | US-09-439-807-209 | Sequence 209, App |
| | 13 | 209 | 23.9 | 209 | 4 | US-09-439-813-209 | Sequence 209, App |
| | 14 | 207 | 23.6 | 207 | 4 | US-08-916-576B-37 | Sequence 37, Appl |
| | 15 | 204 | 23.3 | 204 | 4 | US-08-916-576B-11 | Sequence 11, Appl |
| | 16 | 204 | 23.3 | 204 | 4 | US-08-916-576B-12 | Sequence 12, Appl |
| | 17 | 204 | 23.3 | 204 | 4 | US-08-916-576B-13 | Sequence 13, Appl |
| | 18 | 204 | 23.3 | 204 | 4 | US-08-916-576B-14 | Sequence 14, Appl |
| | 19 | 204 | 23.3 | 204 | 4 | US-08-916-576B-15 | Sequence 15, Appl |
| | 20 | 204 | 23.3 | 204 | 4 | US-08-916-576B-38 | Sequence 38, Appl |
| | 21 | 203 | 23.2 | 203 | 4 | US-08-916-576B-3 | Sequence 3, Appli |
| | 22 | 203 | 23.2 | 203 | 4 | US-08-916-576B-41 | Sequence 41, Appl |
| | 23 | 203 | 23.2 | 203 | 4 | US-08-916-576B-40 | Sequence 40, Appl |
| | 24 | 203 | 23.2 | 203 | 4 | US-08-916-576B-42 | Sequence 42, Appl |
| | 25 | 203 | 23.2 | 203 | 4 | US-08-916-576B-44 | Sequence 44, Appl |
| | 26 | 202 | 23.1 | 202 | 4 | US-09-242-191-8 | Sequence 8, Appli |
| | 27 | 202 | 23.1 | 202 | 4 | US-09-242-211-8 | Sequence 8, Appli |
| | 28 | 202 | 23.1 | 202 | 4 | US-08-916-576B-7 | Sequence 8, Appli |
| | 29 | 202 | 23.1 | 202 | 4 | US-08-916-576B-8 | Sequence 8, Appli |
| | 30 | 202 | 23.1 | 202 | 4 | US-08-916-576B-44 | Sequence 44, Appl |
| | 31 | 202 | 23.1 | 202 | 4 | US-08-916-576B-70 | Sequence 70, Appl |
| | 32 | 202 | 23.1 | 202 | 4 | US-08-916-576B-44 | Sequence 44, Appl |
| | 33 | 202 | 23.1 | 202 | 4 | US-08-916-576B-70 | Sequence 70, Appl |
| | 34 | 202 | 23.1 | 202 | 4 | US-08-916-576B-44 | Sequence 44, Appl |
| | 35 | 202 | 23.1 | 202 | 4 | US-08-916-576B-71 | Sequence 71, Appl |
| | 36 | 202 | 23.1 | 5253 | 4 | US-08-734-918-19 | Sequence 19, Appl |
| | 37 | 202 | 23.1 | 5253 | 4 | US-08-916-576B-19 | Sequence 19, Appl |
| | 38 | 202 | 23.1 | 5253 | 4 | US-09-265-415-19 | Sequence 19, Appl |
| | 39 | 202 | 23.1 | 5253 | 4 | US-09-265-417-19 | Sequence 19, Appl |
| | 40 | 201.5 | 23.0 | 1007 | 4 | US-08-667-648-8 | Sequence 8, Appli |
| | 41 | 201.5 | 23.0 | 2715 | 1 | US-08-475-481-1 | Sequence 1, Appli |
| | 42 | 201.5 | 23.0 | 4673 | 4 | US-08-442-918-44 | Sequence 44, Appl |
| | 43 | 201.5 | 23.0 | 4675 | 4 | US-08-224-881-44 | Sequence 44, Appl |
| | 44 | 201.5 | 23.0 | 4675 | 4 | US-08-916-576A-44 | Sequence 44, Appl |
| | 45 | 201.4 | 23.0 | 682 | 4 | US-08-858-297A-144 | Sequence 144, App |

ALIGNMENTS

RESULT 1
US-08-916-576B-1
; Sequence 1, Application US/08/916,576B
; Patent No. 6171816
; GENERAL INFORMATION:
; APPLICANT: YU, GUO-LIANG
; APPLICANT: DILLON, PATRICK J.
; APPLICANT: LINNEE, REINHARD
; APPLICANT: ENGLESS, GREGORY A.
; TITLE OF INVENTION: NOVEL HUMAN GROWTH FACTORS
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STEVENS, DAVIS, MILLER & MOSHER, L.L.P.
; STREET: 1100 NEW YORK AVENUE, SUITE 600
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: US
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/916,576B
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/240,047
; FILING DATE: 23-AUG-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: STEFFE, ERIC K.
; REGISTRATION NUMBER: 34,668
; REFERENCE/DOCKET NUMBER: 14999.5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 875 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 71..595
; FEATURE:
; NAME/KEY: mat_peptide
; LOCATION: 131..595



; FEATURE:
; NAME/KEY: CDS
; LOCATION: 51..[illegible]
; FEATURE:
; NAME/KEY: sig_peptide
; LOCATION: 51..114
; OTHER INFORMATION: Von Heijne matrix
; OTHER INFORMATION: score: [illegible]
; OTHER INFORMATION: Seq: AFLLVALSYTIA/RI
; FEATURE:
; NAME/KEY: polyA_signal
; LOCATION: 1653..1658
; FEATURE:
; NAME/KEY: polyA_site
; LOCATION: 1674..1686
US-09-247-155-61

Query Match [illegible]%; Score [illegible]; [illegible]; Length 2000;
Best Local Similarity [illegible]%; Pred. No. [illegible];
Matches 524; Conservative [illegible]; Mismatches [illegible]; Indels [illegible]; Gaps [illegible];



RESULT [illegible]
US-09-247-155-14
; Sequence 14, Application US/09/247,155A
; Patent No. 6612922
; GENERAL INFORMATION:
; APPLICANT: Dumas Milne Edwards, Jean-Baptiste
; APPLICANT: Duplant, Aymeric
; APPLICANT: Rouquelaure, Lydie
; TITLE OF INVENTION: Complementary DNAs
; FILE REFERENCE: SENSEI.11A
; CURRENT APPLICATION NUMBER: US/09/247,155A
; CURRENT FILING DATE: [illegible]
; EARLIER APPLICATION NUMBER: 09/[illegible]
; EARLIER FILING DATE: [illegible]

Run on version 3.5

[illegible]

Linear SW model

[illegible] Seconds
(with 1 alignments)
[illegible] Million cell updates/sec

[illegible]

[illegible]

Query 1:

1..[illegible] residue

[illegible]

SUMMARIES

| | | | | | Description |
|---|---|---|---|---|---|
| 1 | US-08-916-576B-1 | | | | Sequence 1, Appli |
| 1 | US-08-247-155-61 | | | | Sequence 61, Appl |
| 1 | US-09-247-155-149 | | | | Sequence 149, App |
| 1 | US-08-084-[illegible] | | | | Sequence 78, Appl |
| 1 | US-08-[illegible]-78 | | | | Sequence 78, Appl |
| 1 | US-08-221-[illegible] | | | | Sequence 32, Appl |
| 1 | US-08-916-576B-35 | | | | Sequence 35, Appl |
| 1 | US-08-916-576B-36 | | | | Sequence 36, Appl |
| 1 | US-08-916-576B-9 | | | | Sequence 9, Appli |
| 1 | US-08-916-576B-10 | | | | Sequence 10, Appl |
| 1 | US-08-916-576B-5 | | | | Sequence 5, Appl |
| 1 | US-09-[illegible] | | | | Sequence 209, App |
| 1 | US-09-439-313-209 | | | | Sequence 209, App |
| 1 | US-08-916-576B-37 | | | | Sequence 37, Appl |
| 1 | US-08-916-576B-38 | | | | Sequence 38, Appl |
| 1 | US-08-916-576B-39 | | | | Sequence 39, Appl |
| 1 | US-08-916-576B-11 | | | | Sequence 11, Appl |
| 1 | US-08-916-576B-12 | | | | Sequence 12, Appl |
| 1 | US-08-916-576B-13 | | | | Sequence 13, Appl |
| 1 | US-08-916-576B-14 | | | | Sequence 14, Appl |
| 1 | US-08-916-576B-15 | | | | Sequence 15, Appl |
| 1 | US-08-916-576B-3 | | | | Sequence 3, Appli |
| 1 | US-08-916-576B-40 | | | | Sequence 40, Appl |
| 1 | US-08-916-576B-41 | | | | Sequence 41, Appl |
| | US-08-[illegible]-1 | | | | Sequence 1, Appli |
| | US-08-[illegible]-1 | | | | Sequence 1, Appli |
| | US-08-[illegible]-1 | | | | Sequence 1, Appli |

| | | | | | | Description |
|---|---|---|---|---|---|---|
| | 28 | 35.6 | 4.1 | 19124 | 2 | US-08-487-828B-28 |
| | 29 | 35.4 | 4.1 | [illegible] | 2 | US-08-[illegible] |
| C | 30 | 35.2 | 4.1 | 1358 | 4 | US-08-[illegible] |
| C | 31 | 35.2 | 4.1 | 4358 | 4 | US-08-[illegible] |
| | 32 | 34.6 | 4.0 | 468 | 4 | US-08-[illegible] |
| C | 33 | 34.4 | 4.0 | 1744 | 1 | US-08-[illegible] |
| C | 34 | 34.4 | 4.0 | 1744 | 1 | US-08-[illegible] |
| C | 35 | 34.4 | 4.0 | 2044 | 1 | DOI:US-[illegible] |
| C | 36 | 34.2 | 4.0 | 1[illegible] | 1 | US-08-[illegible] |
| C | 37 | 34.2 | 4.0 | 2001 | 1 | US-08-[illegible] |
| | 38 | 34 | 4.0 | 45 | 4 | US-08-[illegible] |
| | 39 | 33.8 | 4.0 | 1372 | 2 | US-08-479-614-4 |
| C | 40 | 33.8 | 4.0 | 1372 | 2 | US-08-479-614-6 |
| | 41 | 33.8 | 4.0 | 1385 | 2 | US-08-479-614-7 |
| C | 42 | 33.8 | 4.0 | 1861 | 2 | US-08-479-614-9 |
| C | 43 | 33.6 | 4.0 | 2654 | 1 | US-08-[illegible] |
| C | 44 | 33.6 | 4.0 | 8654 | 1 | US-08-620-827-6 |
| C | 45 | 33.6 | 4.0 | 8654 | 1 | US-08-[illegible] |

| Sequence 14, Appl |
|---|
| Sequence 41, Appl |
| Sequence 8, Appli |
| Sequence 7, Appli |
| Sequence [illegible], Appl |
| Sequence 4, Appli |
| Sequence 5, Appli |
| Sequence 3, Appli |
| Sequence 5a, Appl |
| Sequence 1, Appli |
| Sequence 44, Appl |
| Sequence 4, Appli |
| Sequence 6, Appli |
| Sequence 7, Appli |
| Sequence 9, Appli |
| Sequence 6, Appli |
| Sequence 6, Appli |
| Sequence 6, Appli |

ALIGNMENTS

RESULT 1
US-08-916-576B-1
; Sequence 1, Application US/[illegible]
; Patent No. 6171826
; GENERAL INFORMATION:
; APPLICANT: YU, GUO-LIANG
; APPLICANT: LITTLE, BARRIE J.
; APPLICANT: EBNER, REINHARD
; APPLICANT: ENTRESS, CHRISTY S.
; TITLE OF INVENTION: NOVEL HUMAN 7B WITH PARTIAL
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C.
; STREET: 1100 NEW YORK AVENUE, SUITE
; CITY: WASHINGTON
; STATE: DC
; COUNTRY: US
; ZIP: 2[illegible]
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: FastSEQ for Windows Version [illegible]
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/916,576B
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/024,447
; FILING DATE: 23-AUG-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: STEFFE, ERIC K.
; REGISTRATION NUMBER: 36,688
; REFERENCE/DOCKET NUMBER: 1488.050000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 875 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 71..694
; FEATURE:
; NAME/KEY: mat_peptide
; LOCATION: 143..694

[illegible] treated)
[illegible] last sequence update
[illegible] last annotation update

[illegible]lassol ilori);
[illegible]data: Craniata; Vertebrata; Euteleostomi;
[illegible] Mesobatrachia [illegible]idae;

[illegible]
[illegible]
[illegible]

[illegible]
[illegible]
[illegible]

...identity and ... translated
...regulatory regions which control the
... and quantity of protein synthesis, as
...The ESTs are also useful as probes for
...their full length cDNA clones. The ESTs can
...reduces to identify individuals, or in
...identify individuals having genetic diseases
...expression. The proteins may also be used in
...nucleic acids or polypeptides can be
...signal secretion of a hydrophobic or the
...to a membrane, a hydrophilic polypeptide
...bed by the EST sequences may be useful in
...conditions. Secreted proteins have
...identification of new secreted proteins is
...AAY64644 to AAY64645 represent
...ification of the present invention.

...Score 565; DB 2; Length 115;
...Pred. No. 8.1e-57;
... Mismatches ... Indels 0; Gaps 0;

...FTVRSVSAKKDIKDSPERLAVSIKGWGLSWNMQIYEA 50
...|||||||||||||||||||||||||||||||||||||
...MTSKQRIKKDITKDSRPKLPVSIRGVSIQLIWTQTYEE 50

...HSLALEKVFAENKEIQKLAELSVLNLVYETIDKHISP 115
...|||||||||||||||||||||||||||||||||||||
...KSQRIKKVIAQNKQIQKLAQLSVLNLVYETIDKHISP 115

... AA.

...AA.

...tissue disease; tissue injury;
...to alleviate; cancer; gene therapy;

...clients

...ppt"...

...ppt"...

...ppt"...

...WO...

...SA, Yrs 5;

XX
DR WPI; 1998-169094/15.
DR N-PSDB; AAV19157.
XX
PT New isolated human XAG-2 protein(s) useful to develop drugs for
PT for treating e.g. liver, lung or breast diseases or
PT hyperproliferative disorders - (claimed).
XX
PS Claim 1; Fig 5A-B; 113pp; English.
XX
CC This polypeptide comprises huXAG-2, a member of a new gene family of
CC human growth factors also including huXAG-1 (see AAW47844) and
CC huXAG-2 (see AAW47845). These proteins share homology with the
CC XAG protein of X-enopus laevis, which is involved in embryogenesis
CC and is expressed in adult tissues. huXAG-2 cDNA (see AAV19157) was
CC isolated from a human small intestine cDNA library. Vectors, host
CC cells, antibodies, and screening methods for identifying agonists
CC and antagonists of huXAG-2 are provided. HuXAG polypeptides are
CC growth factors and can be used to stimulate proliferation of cells.
CC They can be used to stimulate the proliferation and differentiation
CC of hepatocytes to alleviate or treat liver diseases and pathologies
CC such as fulminant liver failure caused by cirrhosis, liver damage
CC caused by viral hepatitis and toxic substances. They can also be
CC used to stimulate or promote liver regeneration, e.g. after
CC surgery. They can also be used to prevent and heal damage to the
CC lungs caused by various pathological states. They can be used to
CC stimulate proliferation and differentiation and promote the repair
CC of alveoli and bronchiolar epithelium to prevent, alleviate, or
CC treat acute or chronic lung damage, e.g. emphysema, which results
CC in the progressive loss of alveoli and inhalation injuries, e.g.
CC resulting from smoke inhalation and burns, that cause necrosis of
CC the bronchiolar epithelium and alveoli. They can also be used to
CC stimulate the proliferation and differentiation of breast tissue
CC and could therefore be used to promote healing of breast tissue
CC injury due to surgery, trauma or cancer. Antagonists can be used
CC to treat hyperproliferative disorders, including tumors, in
CC particular hepatocellular carcinoma, osteosarcoma, breast cancer,
CC or colon cancer. The product can also be used in detection and
CC diagnosis.
XX
SQ Sequence 196 AA;

Jy RD # 6 of 6,171,816

Query Match ...%; Score 565; DB 2; Length 196;
Best Local Similarity ...%; Pred. No. 1.4e-56;
Matches 108; Conservative ...; Mismatches 70; Indels 12; Gaps 4;

Qy 10 LLLVALSYIAMIIVKFAKKNDKSPERLPQFLSPWWGNQLIWFQIYFEALYKSKTSN 69
||||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 11 LLLVSVSLIAMIIVKFAKKSEKSPERLPQFLSPWWGNQLIWFQIYFEALYKSKTSN 70

Qy 70 KFLMIIHHEIDETPHSQALEKVFAENKEIQKLAELSVLNLVYETIDKHISPSQLYVDPI 129
||||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 71 KPLMIIHHEIDETPHSQALEKVFAENKEIQKLAELSVLNLVYETIDKHISPSQLYVDPI 130

Qy 130 MFVLPSLIVRADITCRYFNRISAYRLMIALLLLNMKKAIKLKISL 174
||||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db 131 MFVLPSLIVRADITCRYFNRISAYRLMIALLLLNMKKAIKLKISL 175

Search completed: ...
Job time: 123 sec